FINWIRES · TerminalLIVE
FINWIRES

$TAK

20 stories mentioning TAKUpdated 8d ago

Every FINWIRES story that references TAK, newest first.

What's the latest news on TAK?

Asia Markets

Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Monday Trading

Asian equities traded in the US as American depositary receipts started the trading week heading sharply lower Monday morning, falling 1.06% to 2,973.73 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by online game developer Gravity (GRVY) and pharmaceutical company Takeda Pharmaceutical (TAK), which rose 3.1% and 2%, respectively. They were followed by online brokerage UP Fintech (TIGR) and fintech firm Jiayin Group (JFIN), which were up 1.4% each.The decliners from North Asia were led by semiconductor companies Silicon Motion Technology (SIMO) and ASE Technology (ASX), which fell 7.2% and 5.7%, respectively. They were followed by mobile big data platform Aurora Mobile (JG) and semiconductor company Himax Technologies (HIMX), which were down 5.4% each.From South Asia, the gainers were led by IT firms Infosys (INFY) and Wipro (WIT), which advanced 2.9% and 1.8%, respectively. They were followed by telecommunications operator Telekomunikasi Indonesia (TLK) and pharmaceutical company Dr. Reddy's Laboratories (RDY), which increased 1.5% and 0.1%, respectively.The decliners from South Asia were led by IT firm Sify Technologies (SIFY) and lender HDFC Bank (HDB), which lost 1.5% each. They were followed by telecommunications operator PLDT (PHI) and lender ICICI Bank (IBN), which dropped 1.1% and 0.7%, respectively.

$ASX$GRVY$HDB$HIMX$IBN$INFY$JFIN$JG$PHI$RDY$SIFY$SIMO$TAK$TIGR$TLK$WIT
Insider Trading

Takeda Pharmaceutical Insider Sold Shares Worth $2,148,372, According to a Recent SEC Filing

Andrew Stewart Plump, Director, President, Research and Development, on September 02, 2026, sold 116,191 shares in Takeda Pharmaceutical (TAK) for $2,148,372. Following the Form 4 filing with the SEC, Plump has control over a total of 912,034 American depositary shares of the company, with 766,569 shares held directly and 145,465 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1395064/000139506426000335/xslF345X05/wk-form4_1788486556.xml

$TAK
Wire

Update: Market Chatter: Takeda, Other Biotech Firms to Announce New Drug Pricing Deals With White House

(Updates with Bayer's response in the last paragraph.)Takeda Pharmaceutical (TAK), Bayer, CSL, and other mid-size biotech firms are set to announce new pricing deals with the White House on Monday, the Financial Times reported, citing two sources familiar with the matter.The deals will be similar to those finalized by large pharmaceutical companies in which they agreed to lower prices in exchange for tariff relief, according to the report.A Bayer spokesperson said the company had no information to share on the Most Favored Nation drug pricing policy at the moment, while Takeda and CSL did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $18.00, Change: $-0.04, Percent Change: -0.19%

$TAK
Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index decreasing 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.3%.The iShares Biotechnology ETF (IBB) shed 0.4%.In corporate news, Eli Lilly (LLY) has agreed to buy Merida Biosciences for up to $2.875 billion in cash, as it seeks to expand its portfolio of autoimmune and allergic disease therapies, the companies said Monday. Lilly shares were down 1.1%.Takeda Pharmaceutical (TAK), Bayer, CSL, and other mid-size biotech firms are set to announce new pricing deals with the White House on Monday, the Financial Times reported, citing two sources familiar with the matter. The deals will be similar to those finalized by large pharmaceutical companies in which they agreed to lower prices in exchange for tariff relief, according to the report. Takeda shares were down 0.1%.Exelixis (EXEL) said Monday that the US Court of Appeals for the Federal Circuit has affirmed a key portion of the 2024 judgment of the US District Court for the District of Delaware in its favor in the lawsuit Exelixis vs. MSN Laboratories. Exelixis were up 0.4%.Alvotech (ALVO) shares rose past 5% after it said Monday a biologics license application for AVT80 as a proposed interchangeable biosimilar to Entyvio has been accepted for review by the US Food and Drug Administration.

$ALVO$EXEL$LLY$TAK
Sectors

Sector Update: Healthcare

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index decreasing 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.3%.The iShares Biotechnology ETF (IBB) shed 0.4%.In corporate news, Takeda Pharmaceutical (TAK), Bayer, CSL, and other mid-size biotech firms are set to announce new pricing deals with the White House on Monday, the Financial Times reported, citing two sources familiar with the matter. The deals will be similar to those finalized by large pharmaceutical companies in which they agreed to lower prices in exchange for tariff relief, according to the report. Takeda shares were down 0.2%.

$TAK
Wire

Market Chatter: Takeda, Other Biotech Firms to Announce New Drug Pricing Deals With White House

Takeda Pharmaceutical (TAK), Bayer, CSL, and other mid-size biotech firms are set to announce new pricing deals with the White House on Monday, the Financial Times reported, citing two sources familiar with the matter.The deals will be similar to those finalized by large pharmaceutical companies in which they agreed to lower prices in exchange for tariff relief, according to the report.Takeda, Bayer, and CSL did not immediately reply to a request for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $17.99, Change: $-0.05, Percent Change: -0.25%

$TAK
Wire

Protagonist Therapeutics' Own Pipeline Seen as Main Long-Term Growth Driver, Wedbush Says

Protagonist Therapeutics' (PTGX) future growth will hinge more on its wholly owned programs than on its newly approved partner therapy, with the company's first clinical readouts from its proprietary pipeline expected in H1 2027. Wedbush Securities said Monday in a report.Wedbush highlighted PN-8047, an oral version of rusfertide, a treatment recently approved for polycythemia vera and commercialized by Takeda Pharmaceutical (TAK). PN-8047 appears similarly potent and may move into a phase 2 study in 2027 if early safety and iron-lowering data are positive, the report said.Protagonist's cash position is strengthened by payments tied to rusfertide's regulatory approval, including a $200 million opt-out fee and a $75 million milestone, along with similar payments from Johnson & Johnson (JNJ) for icotyde, an oral anti-inflammatory drug being developed for psoriasis and other immune conditions, the report said.Wedbush maintained its outperform rating on Protagonist stock with a $173 price target.Price: $144.35, Change: $+0.02, Percent Change: +0.01%

$JNJ$PTGX$TAK
Asia Markets

Asian Equities Traded in the US as American Depositary Receipts Track Lower in Tuesday Trading

Asian equities traded in the US as American depositary receipts were tracking lower Tuesday morning, declining 1.03% to 2,988.00 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by pharmaceutical company Takeda Pharmaceutical (TAK) and fashion platform MOGU (MOGU), which rose 4.3% and 3.3% respectively. They were followed by tech company Alibaba Group (BABA) and game live-streaming platform HUYA (HUYA), which were up 2.8% and 1.5% respectively.The decliners from North Asia were led by internet and data center services provider VNET Group (VNET) and semiconductor company ASE Technology (ASX), which fell 9.3% and 8.6% respectively. They were followed by tech company Baidu (BIDU) and automotive marketplace Token Cat (TC), which lost 8.5% and 5.7% respectively.From South Asia, the only gainers were lender ICICI Bank (IBN) and IT firm Infosys (INFY), which were up 0.4% and 0.1% respectively.The decliners from South Asia were led by tech conglomerate Sea (SE) and computer hardware maker Canaan (CAN), which dropped 3.5% and 3.3% respectively. They were followed by pharmaceutical company Dr. Reddy's Laboratories (RDY) and telecommunications operator Telekomunikasi Indonesia (TLK), which were off 0.4% and 0.3% respectively.

$ASX$BABA$BIDU$CAN$HUYA$IBN$INFY$MOGU$RDY$SE$TAK$TC$TLK$VNET
Insider Trading

Takeda Pharmaceutical Insider Sold Shares Worth $1,523,439, According to a Recent SEC Filing

Julie So-Young Kim, Director, President and Chief Executive Officer, on August 10, 2026, sold 89,090 shares in Takeda Pharmaceutical (TAK) for $1,523,439. Following the Form 4 filing with the SEC, Kim has control over a total of 391,489 American depositary shares of the company, with 391,489 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1395064/000149315226037484/xslF345X05/ownership.xml

$TAK
Insider Trading

Takeda Pharmaceutical Insider Sold Shares Worth $2,828,220, According to a Recent SEC Filing

Andrew Stewart Plump, Director, President, Research and Development, on August 10, 2026, sold 165,393 shares in Takeda Pharmaceutical (TAK) for $2,828,220. Following the Form 4 filing with the SEC, Plump has control over a total of 1,047,876 American depositary shares of the company, with 766,569 shares held directly and 281,307 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1395064/000149315226037507/xslF345X05/ownership.xml

$TAK
Asia Markets

Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading

Asian equities traded in the US as American depositary receipts were tracking lower Friday morning, declining 0.48% to 2,877.67 on the S&P Asia 50 ADR Index, which is down marginally for the week so far.From North Asia, the gainers were led by education company Four Seasons Education (FEDU) and brand platform 36Kr (KRKR), which climbed 6.8% and 6.7% respectively. They were followed by automotive marketplace Token Cat (TC) and pharmaceutical company Takeda Pharmaceutical (TAK), which advanced 6.1% and 2.6% respectively.The decliners from North Asia were led by video display maker LG Display (LPL) and semiconductor company ASE Technology (ASX), which fell 4.6% and 4% respectively. They were followed by fintech firm High Templar Tech (HTT) and semiconductor company Silicon Motion Technology (SIMO), which were down 3.4% and 2.7% respectively.From South Asia, the gainers were led by IT companies Infosys (INFY) and Wipro (WIT), which increased 2.8% and 2% respectively. They were followed by lender HDFC Bank (HDB) and telecommunications operator PLDT (PHI), which rose 1.4% and 0.3% respectively.The decliners from South Asia were led by computer hardware maker Canaan (CAN) and tech conglomerate Sea (SE), which dropped 2.8% and 1.4% respectively. They were followed by IT firm Sify Technologies (SIFY), which was off 0.4%.

$ASX$CAN$FEDU$HDB$HTT$INFY$KRKR$LPL$PHI$SE$SIFY$SIMO$TAK$TC$WIT
Sectors

Sector Update: Healthcare Stocks Mixed in Afternoon Trading

Healthcare stocks were mixed Friday afternoon, with the NYSE Healthcare Index increasing 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.3%.The iShares Biotechnology ETF (IBB) was up 0.1%.In corporate news, Intuitive Surgical (ISRG) shares fell past 12%. Growth in the company's da Vinci robotic surgery procedures in the US moderated due in part to changes in Affordable Care Act premium subsidies, even as it reported better-than-expected quarterly results.GSK (GSK) shares were down 2.7% after it said Friday it will discontinue development of camlipixant for refractory chronic cough after the drug produced mixed results in the phase 3 CALM-1 and CALM-2 trials.Takeda Pharmaceutical (TAK) shares rose 2%. The company said late Thursday that new phase 3 data showed its oral TYK2 inhibitor, zasocitinib, delivered high rates of skin clearance across difficult-to-treat body sites in adults with moderate-to-severe plaque psoriasis.

$GSK$ISRG$TAK
Asia Markets

Asian Equities Traded in the US as American Depositary Receipts Fall in Friday Trading

Asian equities traded in the US as American depositary receipts were falling on Friday morning, down 1.8% to 2,865.59 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by tech company Youdao (DAO) and used car retailer Uxin (UXIN), which advanced 4.5% and 3.4% respectively. They were followed by pharmaceutical company Takeda (TAK), which climbed 2.9%.The decliners from North Asia were led by semiconductor company United Microelectronics (UMC) and electric vehicle maker Xpeng (XPEV), which fell 5.5% and 5.1% respectively.They were followed by Mizuho Financial (MFG) and semiconductor company ASE Technology (ASX), which dropped 4.1% and 3% respectively.From South Asia, the gainers were led by telecoms Telkom Indonesia (TLK) and PLDT (PHI), which rose 2.9% and 1.6% respectively.The decliners from South Asia were led by tech conglomerate Sea (SE), which fell 4%, followed by technology company Sify Technologies (SIFY), which was down 2.2%.

$ASX$DAO$MFG$PHI$SE$SIFY$TAK$TLK$UMC$UXIN$XPEV
Sectors

Sector Update: Healthcare Stocks Mixed Premarket Friday

Healthcare stocks were mixed premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.4% and the iShares Biotechnology ETF (IBB) 0.7% lower.GSK (GSK) shares were down more than 3% after the company said it will discontinue development of camlipixant for refractory chronic cough after the drug produced mixed results in the phase 3 CALM-1 and CALM-2 trials.Novartis (NVS) shares were up more than 1% after the company said the US Food and Drug Administration approved Fabhalta under the traditional approval pathway to slow kidney function decline in adults with primary immunoglobulin A nephropathy at risk of disease progression.Takeda Pharmaceutical (TAK) shares were 0.6% higher after the company said new phase 3 data showed its oral TYK2 inhibitor, zasocitinib, delivered high rates of skin clearance across difficult-to-treat body sites in adults with moderate-to-severe plaque psoriasis.

$GSK$IBB$NVS$TAK$XLV
Asia Markets

Asian Equities Traded in the US as American Depositary Receipts Surge in Thursday Trading

Asian equities traded in the US as American depositary receipts were surging higher Thursday morning, climbing 2.22% to 2,904.10 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by lender Shinhan Financial Group (SHG) and utilities company Korea Electric Power (KEP), which rose 8% and 4.7% respectively. They were followed by pharmaceutical company Takeda Pharmaceutical (TAK) and automotive company Honda Motor (HMC), which were up 3.6% and 3.4% respectively.The decliners from North Asia were led by automotive marketplace Token Cat (TC) and real estate management and digital security company Eason Technology (DXF), which plunged 37% and 30% respectively. They were followed by automotive marketplaces Uxin (UXIN) and Autohome (ATHM), which decreased 6.2% and 3.5% respectively.From South Asia, the gainers were led by computer hardware maker Canaan (CAN) and IT firm Infosys (INFY), which advanced 4.2% and 3% respectively. They were followed by tech conglomerate Sea (SE) and telecommunications operator PLDT (PHI), which increased 2.2% and 2% respectively.The decliners from South Asia were led by fintech firm Trident Digital Tech (TDTH) and IT company Sify Technologies (SIFY), which fell 1.2% and 1% respectively. They were followed by IT company Wipro (WIT) and lender HDFC Bank (HDB), which were off 0.2% and 0.1% respectively.

$ATHM$CAN$DXF$HDB$HMC$INFY$KEP$PHI$SE$SHG$SIFY$TAK$TC$TDTH$UXIN$WIT
Sectors

Sector Update: Healthcare Stocks Rise Pre-Bell Thursday

Healthcare stocks were rising pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.3% higher and the iShares Biotechnology ETF (IBB) up 0.4%.Ensign Group (ENSG) shares were up more than 2% after the company said it has purchased the real estate and operations of two skilled nursing facilities in Texas.Hutchmed (HCM) stock was up more than 6% after the company said China's National Medical Products Administration granted conditional approval to marketing application of its therapy, Orpathys, to treat certain patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.Takeda Pharmaceutical (TAK) has partnered with Insilico Medicine to use the latter's Pharma.AI platform to advance drug candidates across selected therapeutic areas, Hong Kong-listed Insilico said. Shares of Takeda Pharmaceutical were up more than 2% premarket.

$ENSG$HCM$IBB$TAK$XLV
Asia Markets

Asian Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading

Asian equities traded in the US as American depositary receipts fell Tuesday morning, tumbling 3.1% to 2,816.27 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by mobile app developer Cheetah Mobile (CMCM) and pharmaceutical company Takeda Pharmaceutical (TAK), which rose 2% each. They were followed by travel company Tuniu (TOUR), which was up 0.1%.The decliners from North Asia were led by fintech firm Jiayin Group (JFIN) and semiconductor company ASE Technology (ASX), which fell 29.9% and 7.6% respectively. They were followed by video display maker LG Display (LPL) and semiconductor company Silicon Motion Technology (SIMO), which shed 6.9% and 6.4% respectively.From South Asia, the gainers were led by IT firm Wipro (WIT) and telecommunications operator Telekomunikasi Indonesia (TLK), which increased 3.1% and 1.5% respectively. They were followed by IT firm Infosys (INFY) and pharmaceutical company Dr. Reddy's Laboratories (RDY), which advanced 1% each.The decliners from South Asia were lenders ICICI Bank (IBN) and HDFC Bank (HDB), which were down 1% and 0.5% respectively.

$ASX$CAN$CMCM$IBN$INFY$JFIN$LPL$RDY$SIFY$SIMO$TAK$TDTH$TLK$TOUR$WIT
Asia Markets

Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Monday Trading

Asian equities traded in the US as American depositary receipts opened the trading week sharply higher Monday morning, rising 1.19% to 2,889.22 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by electric vehicle maker NIO (NIO) and semiconductor company Himax Technologies (HIMX), which climbed 6.8% and 6.3% respectively. They were followed by fintech firm Qfin (QFIN) and entertainment streaming service Bilibili (BILI), which advanced 5.8% and 5.1% respectively.The decliners from North Asia were led by real estate management and digital security company Eason Technology (DXF) and mobile app developer Cheetah Mobile (CMCM), which shed 20% and 6.4% respectively. They were followed by solar panel maker JinkoSolar (JKS) and pharmaceutical company Takeda Pharmaceutical (TAK), which dropped 5.4% and 4.2% respectively.From South Asia, the gainers were led by tech conglomerate Sea (SE) and IT firm Infosys (INFY), which rose 5.3% and 2.5% respectively. They were followed by telecommunications operators Telekomunikasi Indonesia (TLK) and PLDT (PHI), which were up 0.4% and 0.1% respectively.The decliners from South Asia were led by computer hardware maker Canaan (CAN) and IT firm Sify Technologies (SIFY), which fell 3.8% and 2.9% respectively. They were followed by pharmaceutical company Dr. Reddy's Laboratories (RDY) and lender ICICI Bank (IBN), which were down 2.1% and 1.3% respectively.

$BILI$CAN$CMCM$DXF$HIMX$IBN$INFY$JKS$NIO$PHI$QFIN$RDY$SE$SIFY$TAK$TLK
Wire

Jury Orders Takeda to Pay Hundreds of Millions in Antitrust Case, Bloomberg Reports

Jury Orders Takeda to Pay Hundreds of Millions in Antitrust Case, Bloomberg Reports

$TAK
Wire

Protagonist Therapeutics Opts Out of Rusfertide US Profit-Sharing Arrangement With Takeda Pharmaceutical

Protagonist Therapeutics (PTGX) exercised its right to opt out of the 50/50 US profit and loss sharing arrangement under its global license and collaboration agreement with Takeda Pharmaceutical (TAK) for rusfertide, Protagonist Therapeutics said Tuesday.As a result, Protagonist Therapeutics will be eligible to receive up to $400 million in opt-out payments.The company will also be entitled to a $75 million milestone payment upon rusfertide's approval in the US and up to $975 million in other milestone payments and tiered royalties on net sales, according to the statement.Takeda Pharmaceutical now holds exclusive development and commercialization rights to rusfertide in the US.Rusfertide is under FDA Priority Review in the US for the treatment of adult patients with polycythemia vera, Protagonist Therapeutics said.Price: $99.31, Change: $+0.84, Percent Change: +0.85%

$PTGX$TAK

Track with the FINWIRES app suite

FolioX
FolioX
Track TAK in your portfolio
WheelAI
WheelAI
Analyze TAK options with the wheel strategy
StockInsider
StockInsider
See market sentiment on TAK